Scarica l'app Stockscreener
121.22
0.98%
-1.20
Dopo l'orario di chiusura:
121.27
0.05
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$122.42
Aprire:
$122.29
Volume 24 ore:
10.42M
Relative Volume:
1.45
Capitalizzazione di mercato:
$150.40B
Reddito:
$29.05B
Utile/perdita netta:
$8.11B
Rapporto P/E:
18.78
EPS:
6.4563
Flusso di cassa netto:
$9.16B
1 W Prestazione:
-3.67%
1M Prestazione:
-1.11%
6M Prestazione:
+9.74%
1 anno Prestazione:
+29.80%
Intervallo 1D:
$120.38
$122.53
Intervallo di 1 settimana:
$120.38
$126.23
Portata 52W:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
121.22 | 152.13B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Marshall Wace LLP Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - GlobeNewswire Inc.
Epoch Investment Partners Inc. Has $95.16 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC - MarketBeat
Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - marketscreener.com
Redeye: Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - TradingView
Is Gilead Sciences Inc. (GIS) stock good for long term investingJuly 2025 Rallies & Stock Timing and Entry Methods - Newser
Gilead's Seat at the Table of Conversations Centered Around HIV - Gilead Sciences
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Channing Capital Management LLC Purchases 43,875 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Guggenheim Capital LLC - MarketBeat
Gilead (GILD) Valuation After Fresh Buy Rating and Extended Biktarvy Exclusivity Boost Investor Confidence - Yahoo Finance UK
Gilead Sciences, Inc. $GILD Shares Bought by Loomis Sayles & Co. L P - MarketBeat
Invesco Ltd. Buys 3,394,330 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) CEO Sells $1,265,400.00 in Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) Director Sells $356,515.50 in Stock - MarketBeat
Gilead Sciences (NASDAQ:GILD) Director Sells $356,670.66 in Stock - MarketBeat
Transcript : Gilead Sciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 11 - marketscreener.com
Insider Activity Update: Jeffrey Bluestone Executes Options Exercise, Resulting In $296K At Gilead Sciences - Benzinga
2,222 Shares in Gilead Sciences, Inc. $GILD Purchased by Valued Retirements Inc. - MarketBeat
Panagora Asset Management Inc. Has $175.96 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Shelton Capital Management Sells 3,380 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Prossimo Advisors LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock outperform value peersWeekly Trend Recap & Comprehensive Market Scan Insights - Newser
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences director Kramer sells $713,186 in stock By Investing.com - Investing.com India
News Is Out hosting Gilead’s Choose U World AIDS Day panel - Dallas Voice
Orleans Capital Management Corp LA Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Railway Pension Investments Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gifford Fong Associates Sells 25,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz - The National Law Review
Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver - Finviz
West Family Investments Inc. Has $1.35 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
New York State Common Retirement Fund Sells 15,100 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Schroder Investment Management Group Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Scotia Capital Inc. Sells 17,090 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Level Four Advisory Services LLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Laurel Wealth Advisors LLC Acquires 6,593 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Edgewood Management LLC Sells 2,394 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What Gilead Sciences (GILD)'s First Lenacapavir Shipments in Africa Mean For Shareholders - simplywall.st
Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - Insider Monkey
Skandinaviska Enskilda Banken AB publ Acquires 252,108 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
WealthTrust Axiom LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
State Board of Administration of Florida Retirement System Purchases 15,800 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Quadrant Capital Group LLC Has $3.82 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Will Expanding Lenacapavir Access in Africa Reshape Gilead Sciences' (GILD) Global Healthcare Narrative? - Yahoo Finance
Is Gilead Sciences a Bargain After 40% Share Price Surge and Pipeline Updates? - Yahoo Finance
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.28%
3.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):